Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study
Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are thought to be part of a spectrum: both have a clinical profile including symptoms associated with dopaminergic and serotonergic loss, yet few imaging studies have focused on serotonergic neurodegeneration in both disorders. We aim...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | NeuroImage: Clinical |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213158219301056 |
| _version_ | 1818422753887256576 |
|---|---|
| author | Merijn Joling Chris Vriend Pieter G.H.M. Raijmakers Jessica J. van der Zande Afina W. Lemstra Henk W. Berendse Jan Booij Odile A. van den Heuvel |
| author_facet | Merijn Joling Chris Vriend Pieter G.H.M. Raijmakers Jessica J. van der Zande Afina W. Lemstra Henk W. Berendse Jan Booij Odile A. van den Heuvel |
| author_sort | Merijn Joling |
| collection | DOAJ |
| description | Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are thought to be part of a spectrum: both have a clinical profile including symptoms associated with dopaminergic and serotonergic loss, yet few imaging studies have focused on serotonergic neurodegeneration in both disorders. We aimed to study degeneration of terminals with dopamine and serotonin transporter (DAT and SERT, respectively) in patients with early-stage PD and DLB relative to healthy controls, using 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) single photon emission computed tomography (SPECT).We conducted region of interest (ROI) and voxel-based analyses on 123I-FP-CIT SPECT scans. Using the cerebellum as a reference region, we determined binding ratios (BRs) for bilateral ROIs in the DAT-rich striatum (head of the caudate nucleus and posterior putamen) and SERT-rich extrastriatal brain regions (thalamus, hypothalamus and hippocampus). We compared BRs in PD and DLB patients with BRs in healthy controls (all groups: n = 16).Both PD and DLB patients had lower striatal 123I-FP-CIT BRs than healthy controls for the bilateral caudate head (PD—left: F(1,29) = 28.778, P < .001, ω2 = 0.35; right: F(1,29) = 35.338, P < .001, ω2 = 0.42; DLB—left: F(1,29) = 28.241, P < .001, ω2 = 0.31; right: F(1,29) = 18.811, P < .001, ω2 = 0.26) and bilateral posterior putamen (PD—left: F(1,29) = 107.531, P < .001, ω2 = 0.77; right: F(1,29) = 87.525, P < .001, ω2 = 0.72; DLB—left: F(1,29) = 39.910, P < .001, ω2 = 0.48; right: F(1,29) = 26.882, P < .001, ω2 = 0.38). DLB patients had lower hypothalamic 123I-FP-CIT BRs than healthy controls (F(1,29) = 6.059, P = .020, ω2 = 0.12). In the voxel-based analysis, PD and DLB patients had significantly lower striatal binding than healthy controls.Both PD patients in the early disease stages and DLB patients have reduced availability of striatal DAT, and DLB patients lower hypothalamic SERT compared with healthy controls. These observations add to the growing body of evidence that PD and DLB are not merely dopaminergic diseases, thereby providing additional clinicopathological insights. Keywords: Parkinson's disease, Dementia with Lewy bodies, 123I-FP-CIT, SERT, DAT |
| first_indexed | 2024-12-14T13:31:16Z |
| format | Article |
| id | doaj.art-8aff0e2ccdf8483f9f577b7846c017f2 |
| institution | Directory Open Access Journal |
| issn | 2213-1582 |
| language | English |
| last_indexed | 2024-12-14T13:31:16Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | NeuroImage: Clinical |
| spelling | doaj.art-8aff0e2ccdf8483f9f577b7846c017f22022-12-21T22:59:42ZengElsevierNeuroImage: Clinical2213-15822019-01-0122Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT studyMerijn Joling0Chris Vriend1Pieter G.H.M. Raijmakers2Jessica J. van der Zande3Afina W. Lemstra4Henk W. Berendse5Jan Booij6Odile A. van den Heuvel7Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam UMC, Univ of Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Corresponding author at: Amsterdam UMC, Location VUmc, Department of Neurology, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.Amsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Neurology, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology, Alzheimer Center, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Neurology, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Neurology, Alzheimer Center, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Neurology, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, NetherlandsAmsterdam UMC, Univ of Amsterdam, Radiology and Nuclear Medicine, Amsterdam Neuroscience, Meibergdreef 9, Amsterdam, NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, NetherlandsParkinson's disease (PD) and dementia with Lewy bodies (DLB) are thought to be part of a spectrum: both have a clinical profile including symptoms associated with dopaminergic and serotonergic loss, yet few imaging studies have focused on serotonergic neurodegeneration in both disorders. We aimed to study degeneration of terminals with dopamine and serotonin transporter (DAT and SERT, respectively) in patients with early-stage PD and DLB relative to healthy controls, using 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) single photon emission computed tomography (SPECT).We conducted region of interest (ROI) and voxel-based analyses on 123I-FP-CIT SPECT scans. Using the cerebellum as a reference region, we determined binding ratios (BRs) for bilateral ROIs in the DAT-rich striatum (head of the caudate nucleus and posterior putamen) and SERT-rich extrastriatal brain regions (thalamus, hypothalamus and hippocampus). We compared BRs in PD and DLB patients with BRs in healthy controls (all groups: n = 16).Both PD and DLB patients had lower striatal 123I-FP-CIT BRs than healthy controls for the bilateral caudate head (PD—left: F(1,29) = 28.778, P < .001, ω2 = 0.35; right: F(1,29) = 35.338, P < .001, ω2 = 0.42; DLB—left: F(1,29) = 28.241, P < .001, ω2 = 0.31; right: F(1,29) = 18.811, P < .001, ω2 = 0.26) and bilateral posterior putamen (PD—left: F(1,29) = 107.531, P < .001, ω2 = 0.77; right: F(1,29) = 87.525, P < .001, ω2 = 0.72; DLB—left: F(1,29) = 39.910, P < .001, ω2 = 0.48; right: F(1,29) = 26.882, P < .001, ω2 = 0.38). DLB patients had lower hypothalamic 123I-FP-CIT BRs than healthy controls (F(1,29) = 6.059, P = .020, ω2 = 0.12). In the voxel-based analysis, PD and DLB patients had significantly lower striatal binding than healthy controls.Both PD patients in the early disease stages and DLB patients have reduced availability of striatal DAT, and DLB patients lower hypothalamic SERT compared with healthy controls. These observations add to the growing body of evidence that PD and DLB are not merely dopaminergic diseases, thereby providing additional clinicopathological insights. Keywords: Parkinson's disease, Dementia with Lewy bodies, 123I-FP-CIT, SERT, DAThttp://www.sciencedirect.com/science/article/pii/S2213158219301056 |
| spellingShingle | Merijn Joling Chris Vriend Pieter G.H.M. Raijmakers Jessica J. van der Zande Afina W. Lemstra Henk W. Berendse Jan Booij Odile A. van den Heuvel Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study NeuroImage: Clinical |
| title | Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study |
| title_full | Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study |
| title_fullStr | Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study |
| title_full_unstemmed | Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study |
| title_short | Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study |
| title_sort | striatal dat and extrastriatal sert binding in early stage parkinson s disease and dementia with lewy bodies compared with healthy controls an 123i fp cit spect study |
| url | http://www.sciencedirect.com/science/article/pii/S2213158219301056 |
| work_keys_str_mv | AT merijnjoling striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT chrisvriend striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT pieterghmraijmakers striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT jessicajvanderzande striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT afinawlemstra striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT henkwberendse striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT janbooij striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy AT odileavandenheuvel striataldatandextrastriatalsertbindinginearlystageparkinsonsdiseaseanddementiawithlewybodiescomparedwithhealthycontrolsan123ifpcitspectstudy |